Yinchenhao Decoction Protects Against Severe Acute Pancreatitis-Associated Liver Injury Through Suppression of Hepatic TLR4/NF-?B/NLRP3 Signalling
Digestion · 2026-10-29
DOI: 10.1159/dig/acmag033 ↗Abstract
Introduction: Liver injury is a major complication of severe acute pancreatitis (SAP) and is associated with poor clinical outcomes, yet effective pharmacological interventions remain limited. Yinchenhao decoction (YCHD), a classical traditional Chinese medicine formula, has shown anti-inflammatory and organ-protective properties. However, its role and underlying mechanism in SAP-associated liver injury remain unclear. Methods: SAP was induced in mice by retrograde infusion of 2% sodium taurocholate into the biliopancreatic duct. Pancreatic, hepatic, and serum samples were collected 24 h after SAP induction and treatment. Histopathological injury and serum biochemical indices were assessed. The hepatic expression of TLR4/NF-κB/NLRP3 pathway-related molecules was evaluated by qPCR and western blotting. The hepatic distribution of major YCHD-derived compounds was characterized by HPLC-MS/MS. Results: YCHD markedly reduced serum amylase, alanine aminotransferase, and aspartate aminotransferase levels, and alleviated histopathological injury in both pancreatic and hepatic tissues. Mechanistically, YCHD suppressed the hepatic mRNA expression of TLR4, NF-κB, NLRP3, and ASC, and reduced the protein levels of key inflammatory mediators associated with TLR4/NF-κB/NLRP3 signalling. HPLC-MS/MS analysis identified multiple YCHD-derived compounds in liver tissue, among which geniposide showed the highest hepatic abundance. Conclusion: YCHD protects against SAP-associated liver injury, at least in part, through suppression of the hepatic TLR4/NF-κB/NLRP3 inflammatory axis. The prominent hepatic accumulation of geniposide suggests that it may represent one of the principal bioactive constituents contributing to the therapeutic effects of YCHD.
EUVIMED